Omada Health, Inc. Common Stock (OMDA) Fair Value & Analysis
Healthcare · US · Market cap $1.0B · ISIN US68170A1088
What is Omada Health, Inc. Common Stock really worth?
Omada Health, Inc. Common Stock
OMDA · US
A solid business, but trading 200% above our fair value of $7.44.
Strengths
Risks
Fair value as of: Aug 30, 2026
From 7 valuation models · updated 6 days ago
Share price +10.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($8.55). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (15 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 30, 2026.
How to read this chart
15‑month range $10.94 – $26.78 · fair‑value band $6.33 – $8.55 · the $22.29 price screens above the $7.44 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 30, 2026.
Analysis
Omada Health, Inc. Common Stock (OMDA) currently trades at $22.29, while our model-based Fair Value estimate is $7.44, implying the stock looks roughly 199.6% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: the Growth DCF group reads highest at a median of $9.34 per share, and 0 of the 7 models we run sit above the $22.29 price. Bear case: the Asset-Based group reads lowest at $2.59, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Omada Health, Inc. Common Stock generated revenue of $283M at a net margin of −2.2%. Revenue grew 42.0% year over year. It earns a return on equity of −4.3%. The balance sheet holds a net cash position of $222M. Fundamentals as of Aug 30, 2026
Our scenario range runs from $6.33 (bear case) to $8.55 (bull case); at $22.29, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 117% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −68% fair-value upside, at −67%, OMDA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 7 models by family
Widest divergence: Growth DCF ($9.34) versus Asset-Based ($2.59). Highest evidence: FCF DCF (75).
Notify me when OMDA reaches fair value
Put OMDA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 30, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 41
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States.
Full company description
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Omada Health, Inc. Common Stock reported revenue of $260M in FY2025 versus $89.2M in FY2022, a compound +42.9%/yr. Reported net income was −$12.8M in FY2025.
OMDA screens 200% overvalued. Compare with Veeva Systems Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Omada Health (OMDA) Q2 2026 Earnings Call Transcript
- Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy
- Omada Health CEO Sean Duffy Sells 17,000 Shares. What Does This Mean for Investors?
- Omada Health, Inc. (OMDA) Stock Jumps 10.5%: Will It Continue to Soar?
Peer Group
Health Information Services · 128 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 42/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 30, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $282.13 | $91.49 | −68% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | −87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | −64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | −46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | −72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | −69% |
| Waystar Holding WAY | $25.76 | $12.86 | −50% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | −87% |
| Doximity, Inc DOCS | $24.74 | $25.91 | +5% |
| Privia Health Group PRVA | $21.07 | $5.26 | −75% |
Compare Omada Health, Inc. Common Stock with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Omada Health, Inc. Common Stock (OMDA) overvalued or undervalued?
What is the fair value of OMDA?
What is the quality score of OMDA?
What is the revenue of Omada Health, Inc. Common Stock (OMDA)?
What is the net profit margin of OMDA?
Watch Omada Health, Inc. Common Stock in the live analysis
One click puts Omada Health, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.